Project 2: Subtype Specification and Arrhythmogenic Potential of Stem Cell Derived Cardiomyocytes. Cardiomyocytes derived from human embryonic stem cells (hESCs) have tremendous promise for cardiac repair, both for replacing ventricular myocardium after an infarct and serving as a "biologic pacemaker" in diseases like sick-sinus syndrome. We have reported methods to generate large quantities of highly purified cardiomyocytes from hESCs, but these preparations include cells with distinct nodal/pacemaker and "working" (i.e. chamber-like) phenotypes. For these cells to be useful and safe, they must have electrophysiological properties matched to each application. Hence, this project will develop approaches to control the cardiac subtype of hESC derivatives and then will determine their electrophysiological behavior following transplantation in intact and infarcted hearts.
In Aim 1, we will develop a genetic selection system to follow the lineage relationships of cardiac subtypes derived from hESCs. This work builds on our preliminary findings that a promoter element from the cGATA6 gene identifies hESC-derived cardiomyocytes with the nodal phenotype.
In Aim 2, we will elucidate the molecular events by which neuregulin/ErbB signaling regulates the cardiac subtype of hESC-derived cardion yocytes. This work will employ the genetic reporters from Aim 1 but will also lead to complementary pharmacological approaches to control cardiac subtype specification.
In Aim 3, we will address two uncertainties regarding the electrophysiological behavior of hESC-derived cardiomyocytes following transplantation. First, we will test whether these cells are electrically coupled and beat synchronously with host muscle in normal and infarcted hearts. Second, we will test the hypothesis that their transplantation will modulate the incidence of infarct-related arrhythmias, while the incidence of graft-associated arrhythmias can be "tuned" by controlling the phenotype of the input cell preparation.
Stem-cell derived heart muscle cells have promise both for repair of myocardial infarcts (heart attacks) and use as a biologic pacemaker. However, these cells must have the appropriate electrical properties for each application. In this project, we will develop approaches to controlling their electrical behavior and then will determine whether their intra-cardiac transplantation increases or decreases the incidence of arrhythmias.
|Lundy, Scott D; Gantz, Jay A; Pagan, Chelsea M et al. (2014) Pluripotent stem cell derived cardiomyocytes for cardiac repair. Curr Treat Options Cardiovasc Med 16:319|
|Jiao, Alex; Trosper, Nicole E; Yang, Hee Seok et al. (2014) Thermoresponsive nanofabricated substratum for the engineering of three-dimensional tissues with layer-by-layer architectural control. ACS Nano 8:4430-9|
|Chong, James J H; Murry, Charles E (2014) Cardiac regeneration using pluripotent stem cells--progression to large animal models. Stem Cell Res 13:654-65|
|Coulombe, Kareen L K; Bajpai, Vivek K; Andreadis, Stelios T et al. (2014) Heart regeneration with engineered myocardial tissue. Annu Rev Biomed Eng 16:1-28|
|Lundy, Scott D; Murphy, Sean A; Dupras, Sarah K et al. (2014) Cell-based delivery of dATP via gap junctions enhances cardiac contractility. J Mol Cell Cardiol 72:350-9|
|Hartman, Matthew E; Liu, Yonggang; Zhu, Wei-Zhong et al. (2014) Myocardial deletion of transcription factor CHF1/Hey2 results in altered myocyte action potential and mild conduction system expansion but does not alter conduction system function or promote spontaneous arrhythmias. FASEB J 28:3007-15|
|Yang, Xiulan; Pabon, Lil; Murry, Charles E (2014) Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Res 114:511-23|
|Thomson, Kassandra S; Dupras, Sarah K; Murry, Charles E et al. (2014) Proangiogenic microtemplated fibrin scaffolds containing aprotinin promote improved wound healing responses. Angiogenesis 17:195-205|
|Shiba, Yuji; Filice, Dominic; Fernandes, Sarah et al. (2014) Electrical Integration of Human Embryonic Stem Cell-Derived Cardiomyocytes in a Guinea Pig Chronic Infarct Model. J Cardiovasc Pharmacol Ther 19:368-381|
|Bahrami, Arya J; Gunaje, Jagadambika J; Hayes, Brian J et al. (2014) Regulator of G-protein signaling-5 is a marker of hepatic stellate cells and expression mediates response to liver injury. PLoS One 9:e108505|
Showing the most recent 10 out of 44 publications